Abstract:We recently identified two virulence-associated small open reading frames (sORF) of Yersinia pestis , named yp1 and yp2 , and null mutants of each individual genes were highly attenuated in virulence. Plague vaccine strain EV76 is known for strong reactogenicity, making it not suitable for use in humans. To improve the immune safety of EV76, three mutant strains of EV76, Δ yp1 , Δ yp2 , and Δ yp1&yp2 were constructed and their virulence attenuation, immunogenicity, and protective efficacy in mice were evaluated. All mutant strains were attenuated by the subcutaneous ( s . c .) route and exhibited more rapid clearance in tissues than the parental strain EV76. Under iron overload conditions, only the mice infected with EV76Δ yp1 survived, accompanied by less draining lymph nodes damage than those infected by EV76. Analysis of cytokines secreted by splenocytes of immunized mice found that EV76Δ yp2 induced higher secretion of multiple cytokines including TNF-α, IL-2, and IL-12p70 than EV76. On day 42, EV76Δ yp2 or EV76Δ yp1&yp2 immunized mice exhibited similar protective efficacy as EV76 when exposed to Y . pestis 201, both via s . c . or intranasal ( i . n .) routes of administration. Moreover, when exposed to 200–400 LD 50 Y . pestis strain 201Δ caf1 (non-encapsulated Y . pestis ), EV76Δ yp2 or EV76Δ yp1&yp2 are able to afford about 50% protection to i . n . challenges, significantly better than the protection afforded by EV76. On 120 day, mice immunized with EV76Δ yp2 or EV76Δ yp1&yp2 cleared the i . n . challenge of Y . pestis 201- lux as quickly as those immunized with EV76, demonstrating 90–100% protection. Our results demonstrated that deletion of the yp2 gene is an effective strategy to attenuate virulence of Y . pestis EV76 while improving immunogenicity. Furthermore, EV76Δ yp2 is a promising candidate for conferring protection against the pneumonic and bubonic forms of plague. Y . pestis , the causative agent of the deadly plague, has caused three global pandemics throughout history and continues to pose a significant threat in various regions of the world. Unfortunately, there are currently no approved vaccines available to safeguard humans against Y . pestis infection. While the live-attenuated Y . pestis EV76 vaccine strain has been utilized in high-risk populations in China, Mongolia, and former Soviet countries, its usage is restricted due to potential severe adverse effects. In a recent study, we identified two small open reading frames (sORF)-encoded peptides of Y . pestis , namely SEP-yp1 and SEP-yp2, which are associated with the bacterium's virulence. To improve the safety and efficacy of the EV76 vaccine, we constructed three mutant strains (Δ yp1 , Δ yp2 , and Δ yp1&yp2 ) and evaluated their virulence attenuation, immunogenicity, and ability to protect against Y . pestis infection in mice. Our findings demonstrated that deleting the yp2 gene was a successful approach to diminish the virulence of Y . pestis EV76 while simultaneously enhancing its ability to provoke an immune response. Furthermore, our study revealed that EV76Δ yp2 exhibited superior protection against different forms of plague, including pneumonic and bubonic, making it a promising candidate for further development as a plague vaccine.

Protein Microarray for Profiling Antibody Responses to Yersinia Pestis Live Vaccine

Identification and Evaluation of Novel Antigen Candidates Against Salmonella Pullorum Infection Using Reverse Vaccinology.

Annotation of Potential Vaccine Targets and Design of a Multi-Epitope Subunit Vaccine Against Yersinia Pestis Through Reverse Vaccinology and Validation Through an Agent-Based Modeling Approach

Cloning and Expression of the Specific Genes from Yersinia Pestis and Analysis of Their Antigenicity

Kinetics of Memory B Cell and Plasma Cell Responses in the Mice Immunized with Plague Vaccines

Construction and Immunogenicity of Fused Gene Containing Protective Antigen F1-V of Yersinia Pestis and Signal Peptide of Human Tpa

Evaluation of human antibodies from vaccinated volunteers for protection against Yersinia pestis infection

Relative Immunogenicity and Protection Potential of Candidate Yersinia Pestis Antigens Against Lethal Mucosal Plague Challenge in Balb/C Mice.

In Silico Analysis and Immune Response of YaeT Protein Against Riemerella anatipestifer in Ducks

Systematic Analysis of Natural Antibody Responses to P. Falciparum Merozoite Antigens by Protein Arrays.

Isolation of camel single domain antibodies against Yersinia pestis V270 antigen based on a semi-synthetic single domain antibody library and development of a VHH-based lateral flow assay

Porcine antibody profiles of 33 Mycoplasma hyopneumoniae fusion proteins from M. hyopneumoniae natural infection but not vaccination

Prokaryotic Expression and Priliminary Evaluation of the Immunization Efficacy of Varicella-Zoster Virus Glycoprotein E

Whole Yeast Vaccine Displaying ZIKV B and T Cell Epitopes Induces Cellular Immune Responses in the Murine Model

Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy

Characterization of the Enterovirus 71 P1 Polyprotein Expressed Inpichia Pastoras a Candidate Vaccine

Decrypting the multi-genome data for chimeric vaccine designing against the antibiotic resistant Yersinia pestis

A novel sORF gene mutant strain of Yersinia pestis vaccine EV76 offers enhanced safety and improved protection against plague

NSOM‐ and AFM‐based Nanotechnology Elucidates Nano‐structural and Atomic‐force Features of a Y. Pestis V Immunogen‐containing Particle Vaccine Capable of Eliciting Robust Response

Immunoproteomic analysis of Brucella melitensis and identification of a new immunogenic candidate protein for the development of brucellosis subunit vaccine

Application of a Neisseria meningitidis antigen microarray to identify candidate vaccine proteins from a human Phase I clinical trial